ALPINE GROUP PARTNERS, LLC. lobbying for EMERGENT BIOSOLUTIONS

Filing 4th Quarter - Termination

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 17, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

Maryland

Representation ended

Dec 31, 2025

The registrant reported terminating its work for this client.

Official filing document

Lobbyists on this filing 2

HANNAH SCHMIDT

Previously held: Professional Staff, House Small Business Cmte
ERIN MENDELSOHN

Previously held: LD, Rep. Anna Eshoo; Congressional Liaison - FDA

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
HR 2483
SUPPORT for Patients and Communities Reauthorization Act of 2025
HR 5252
HOPE Act

Lobbying activity 2

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act

Aviation/Airlines/Airports

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act